



## 10th Anniversary of Antibiotics—Recent Advances in Bacteriophage Therapy

Guest Editor:

**Prof. Dr. Adelaide Almeida**

Departamento de Biologia,  
CESAM - Centro de Estudos do  
Ambiente e do Mar, Campus  
Universitário de Santiago,  
Universidade de Aveiro, 3810-193  
Aveiro, Portugal

Deadline for manuscript  
submissions:

**closed (31 December 2021)**

### Message from the Guest Editor

The *Antibiotics* journal was founded in 2012 and, during the past 10 years, has launched more than 100 Special Issues and published more than 1500 papers. The journal covers all aspects of antibiotic discovery, use and preservation. The year 2021 marks the 10th anniversary of *Antibiotics*, which we are excited to celebrate with a Special Issue.

This Special Issue welcomes both research and review papers on the most recent and innovative developments in phage therapy bacteriophages. We hope that the Special Issue can further encourage and promote the scientific contributions of the researchers in this field, highlighting the advances in phage therapy in both clinical and nonclinical areas, namely:

- Phage therapy against multidrug-resistant bacteria, intracellular bacteria, bacteria capable of forming biofilms, and bacteria involved in chronic infections;
- The impact of phage use on the environment;
- The effects of environmental factors on phage viability;
- The functional stabilization/preservation of phage particles;
- Phage administration routes, phage concentrations, and moments of treatment;
- Phage specificity to target bacteria





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Nicholas Dixon

School of Chemistry and  
Molecular Bioscience, University  
of Wollongong, Wollongong, NSW  
2522, Australia

## Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPUS / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1  
(*General Pharmacology, Toxicology and Pharmaceutics*)

## Contact Us

*Antibiotics* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/antibiotics](http://mdpi.com/journal/antibiotics)  
[antibiotics@mdpi.com](mailto:antibiotics@mdpi.com)  
[X@antibioticsmdpi](https://twitter.com/antibioticsmdpi)